BioCentury
ARTICLE | Financial News

Mersana raises $33M in series C round

June 17, 2016 12:32 AM UTC

Antibody-drug conjugate (ADC) developer Mersana Therapeutics Inc. (Cambridge, Mass.) raised $33 million in a series C round led by new investor Wellington Management Company. Also participating were new investors Cormorant Asset Management, Arrowpoint Partners and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), and existing investors New Enterprise Associates and Rock Springs Capital.

Mersana's Fleximer technology is designed to conjugate a biodegradable hydrophilic polymer to a mAb using a non-releasing linker, to which a payload is added. ...